The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
- PMID: 7628178
- DOI: 10.1016/0009-9236(95)90067-5
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
Abstract
The pharmacokinetics of cyclosporine were studied in the blood of five normal healthy volunteers (two men and three women) after each received oral and intravenous cyclosporine alone and with concomitant oral ketoconazole. Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration. Steady-state volume of distribution for intravenously administered cyclosporine was unchanged (1.26 +/- 0.44 L/kg versus 1.10 +/- 0.27 L/kg). Hepatic bioavailability (1 - hepatic extraction ratio) calculated for intravenous cyclosporine increased by 11% in the presence of ketoconazole (86.3% +/- 3.7% versus 75.2% +/- 6.6% without ketoconazole), which accounts for only one third of the observed increase in cyclosporine oral bioavailability. Because it is unlikely that ketoconazole had a significant effect on either cyclosporine absorption or hepatic blood flow, the increase in cyclosporine bioavailability observed in this study is most likely explained by inhibition of gastrointestinal cytochrome P450 enzymes.
Similar articles
-
Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine.Clin Pharmacol Ther. 1995 Nov;58(5):492-7. doi: 10.1016/0009-9236(95)90168-X. Clin Pharmacol Ther. 1995. PMID: 7586942
-
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.Clin Pharmacol Ther. 1999 Nov;66(5):461-71. doi: 10.1016/S0009-9236(99)70009-3. Clin Pharmacol Ther. 1999. PMID: 10579473
-
Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.Clin Pharmacol Ther. 2002 Dec;72(6):718-28. doi: 10.1067/mcp.2002.129068. Clin Pharmacol Ther. 2002. PMID: 12496753 Clinical Trial.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Oral versus intravenous vinorelbine: clinical safety profile.Expert Opin Drug Saf. 2005 Sep;4(5):915-28. doi: 10.1517/14740338.4.5.915. Expert Opin Drug Saf. 2005. PMID: 16111453 Review.
Cited by
-
Enzymatic activities in the microsomes prepared from rat small intestinal epithelial cells by differential procedures.Pharm Res. 2001 Aug;18(8):1232-6. doi: 10.1023/a:1010951732288. Pharm Res. 2001. PMID: 11587497 No abstract available.
-
Loss of orally administered drugs in GI tract.Saudi Pharm J. 2012 Oct;20(4):331-44. doi: 10.1016/j.jsps.2012.03.005. Epub 2012 Apr 20. Saudi Pharm J. 2012. PMID: 23960808 Free PMC article.
-
Membrane transporters in drug development.Nat Rev Drug Discov. 2010 Mar;9(3):215-36. doi: 10.1038/nrd3028. Nat Rev Drug Discov. 2010. PMID: 20190787 Free PMC article. Review.
-
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.Br J Clin Pharmacol. 1999 Nov;48(5):716-27. doi: 10.1046/j.1365-2125.1999.00073.x. Br J Clin Pharmacol. 1999. PMID: 10594474 Free PMC article.
-
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.Clin Pharmacokinet. 2018 Sep;57(9):1075-1106. doi: 10.1007/s40262-018-0639-4. Clin Pharmacokinet. 2018. PMID: 29512050 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources